TY - JOUR
T1 - Blood–tumor barrier opening changes in brain metastases from pre to one-month post radiation therapy
AU - Teng, Feifei
AU - Tsien, Christina I.
AU - Lawrence, Theodore S.
AU - Cao, Yue
N1 - Funding Information:
This study was funded by NIH/NCI grant of R21 CA113699. Also, Y.C.’s research is funded by NIH grants of U01CA183848, RO1CA184153, P01 CA059827, and RO1 EB016079, and industry grants of Siemens Healthineers and Epicentrix, Inc. T.S.L.’s research is supported by NIH P01 CA059827. Appendix A
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/10
Y1 - 2017/10
N2 - Purpose Blood–tumor barrier is a limiting factor for effectiveness of systemic therapy to brain metastases. This study aimed to assess the extent and time course of BTB opening in BM following whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) to determine optimal timing for systemic therapy. Materials and method 30 patients received WBRT or SRS and a total of 64 metastatic lesions were analyzed. Dynamic contrast-enhanced MRI were acquired, to quantify a transfer constant (Ktrans), pre-RT, 1–2 weeks after starting RT (Wk1-2), and 1-month post-RT (1 M post-RT). Lesions were categorized as either low or high permeability based upon the pre-RT percentage volume of a lesion with Ktrans > 0.005 min−1 (%Vall) less or greater than 50%. Time-course changes of %Vall after RT were analyzed. Results Fifty-seven lesions had high-permeability and seven had low-permeability at baseline. Intra-patient and inter-lesion heterogeneity was observed in six patients who had both low- (n = 7) and high-permeability lesions (n = 10). Also, lesion permeability showed a significant size-effect at baseline. For high-permeability lesions, either received WBRT (n = 43) or SRS (n = 14), %Vall decreased non-significantly following RT (from 85.4% pre-RT to 76.9% 1 M post-RT). For low-permeability lesions (n = 7, all received WBRT), %Vall increased from 5.6% pre-RT to 30.2% at Wk1-2 and to 52.6% 1 M−post (p = 0.01). Conclusion Our preliminary results suggest that 2–4 weeks after RT, when BTB opening is high for both low- and high-permeability brain metastatic lesions, could be optimal time to start systemic therapy.
AB - Purpose Blood–tumor barrier is a limiting factor for effectiveness of systemic therapy to brain metastases. This study aimed to assess the extent and time course of BTB opening in BM following whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) to determine optimal timing for systemic therapy. Materials and method 30 patients received WBRT or SRS and a total of 64 metastatic lesions were analyzed. Dynamic contrast-enhanced MRI were acquired, to quantify a transfer constant (Ktrans), pre-RT, 1–2 weeks after starting RT (Wk1-2), and 1-month post-RT (1 M post-RT). Lesions were categorized as either low or high permeability based upon the pre-RT percentage volume of a lesion with Ktrans > 0.005 min−1 (%Vall) less or greater than 50%. Time-course changes of %Vall after RT were analyzed. Results Fifty-seven lesions had high-permeability and seven had low-permeability at baseline. Intra-patient and inter-lesion heterogeneity was observed in six patients who had both low- (n = 7) and high-permeability lesions (n = 10). Also, lesion permeability showed a significant size-effect at baseline. For high-permeability lesions, either received WBRT (n = 43) or SRS (n = 14), %Vall decreased non-significantly following RT (from 85.4% pre-RT to 76.9% 1 M post-RT). For low-permeability lesions (n = 7, all received WBRT), %Vall increased from 5.6% pre-RT to 30.2% at Wk1-2 and to 52.6% 1 M−post (p = 0.01). Conclusion Our preliminary results suggest that 2–4 weeks after RT, when BTB opening is high for both low- and high-permeability brain metastatic lesions, could be optimal time to start systemic therapy.
KW - Blood–tumor barrier
KW - Brain metastasis
KW - DCE MRI
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85027982510&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2017.08.006
DO - 10.1016/j.radonc.2017.08.006
M3 - Article
C2 - 28835339
AN - SCOPUS:85027982510
SN - 0167-8140
VL - 125
SP - 89
EP - 93
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 1
ER -